BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
German police 'cleared path for fascists with batons,' protesters say- Dependable Savvy Locks to Update Your Home Security
- Would you ever turn to AI for companionship? 6% of Americans say they could — or already have.
- Flourishing in a Cutthroat Work Market: Vocation Methodologies
- A definitive Manual for the 5 Off-road Bicycles Available
- Tech for Wellbeing: Applications and Devices for a Better You
- Audits of the Top Science fiction Movies This Year
- Famous Kitchen Finishing Styles For 2024
- Tech Patterns 2023: 12 Advancements to Keep an eye Out For
